AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease

Table 3 Performance of combinations of candidate biomarkers

Combination	TP	FP	TN	FN	sensitivity (HCC = 50)	specificity (LC = 41)	TPP	TPN	LR
afp	28	0	41	22	56.00%	100.00%	100.0%	65.10%	-
afp+piv	47	8	33	3	94.00%	80.50%	85.50%	91.70%	4.82
piv	39	8	33	11	78.00%	80.50%	83.00%	75.00%	4
afp+scca	36	11	30	14	72.00%	73.20%	76.60%	68.20%	2.68
afp+piv+scca	45	16	25	5	90.00%	61.00%	73.80%	83.30%	2.31
piv+scca	42	16	25	8	84.00%	61.00%	72.40%	75.80%	2.15
gcp+scca	36	16	25	14	72.00%	61.00%	69.20%	64.10%	1.85
afp+gcp	41	22	19	9	82.00%	46.30%	65.10%	67.90%	1.53
afp+piv+gcp	48	27	14	2	96.00%	34.10%	64.00%	87.50%	1.46
gcp+piv	46	27	14	4	92.00%	34.10%	63.00%	77.80%	1.4
all	48	31	10	2	96.00%	24.40%	60.80%	83.30%	1.27
gcp	34	22	19	16	68.00%	46.30%	60.70%	54.30%	1.27
gcp+piv+scca	47	31	10	3	94.00%	24.40%	60.30%	76.90%	1.24
afp+gcp+scca	36	28	13	14	72.00%	31.70%	56.30%	48.10%	1.05
scca	9	11	30	41	18.00%	73.20%	45.00%	42.30%	0.67

The true and false positive (TP and FP), as well as true and false negative (TN and FN) for each candidate either alone or in combination is presented, along with sensitivity, specificity, true percentage positive (TPP) and true percentage negative (TPN) values and the liklihood ratio (LR). The LR is the ratio of true and false positives (sensitivity and 1-specificity respectively), where higher values reflect the probability of a better performance.

ISSN: 1471-2407